AVTX Stock Summary and Trading Ideas (Avalo Therapeutics | NASDAQ:AVTX)

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Avalo Therapeutics trades on the NASDAQ stock market under the symbol AVTX.

As of January 15, 2025, AVTX stock price climbed to $6.53 with 377 million shares trading.

AVTX has a beta of 0.88, meaning it tends to be less sensitive to market movements. AVTX has a correlation of 0.00 to the broad based SPY ETF.

AVTX has a market cap of $68.33 million. This is considered a Micro Cap stock.

In the last 3 years, AVTX traded as high as $3,023.77 and as low as $3.95.

The top ETF exchange traded funds that AVTX belongs to (by Net Assets): VXF.

AVTX has underperformed the market in the last year with a price return of +14.2% while the SPY ETF gained +25.7%. AVTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -29.7% and -12.1%, respectively, while the SPY returned +1.6% and +1.0%, respectively.

AVTX support price is $6.03 and resistance is $7.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVTX shares will trade within this expected range on the day.